767 related articles for article (PubMed ID: 30295933)
1. Hereditary transthyretin-related amyloidosis.
Finsterer J; Iglseder S; Wanschitz J; Topakian R; Löscher WN; Grisold W
Acta Neurol Scand; 2019 Feb; 139(2):92-105. PubMed ID: 30295933
[TBL] [Abstract][Full Text] [Related]
2. Diagnosis and management of transthyretin familial amyloid polyneuropathy in Japan: red-flag symptom clusters and treatment algorithm.
Sekijima Y; Ueda M; Koike H; Misawa S; Ishii T; Ando Y
Orphanet J Rare Dis; 2018 Jan; 13(1):6. PubMed ID: 29343286
[TBL] [Abstract][Full Text] [Related]
3. Origin of sporadic late-onset hereditary ATTR Val30Met amyloidosis in Japan.
Ueda M; Yamashita T; Misumi Y; Masuda T; Ando Y
Amyloid; 2018 Sep; 25(3):143-147. PubMed ID: 30486687
[TBL] [Abstract][Full Text] [Related]
4. Hereditary transthyretin-related amyloidosis is frequent in polyneuropathy and cardiomyopathy of no obvious aetiology.
Skrahina V; Grittner U; Beetz C; Skripuletz T; Juenemann M; Krämer HH; Hahn K; Rieth A; Schaechinger V; Patten M; Tanislav C; Achenbach S; Assmus B; Knebel F; Gingele S; Skrahin A; Hartkamp J; Förster TM; Roesner S; Pereira C; Rolfs A
Ann Med; 2021 Dec; 53(1):1787-1796. PubMed ID: 34658264
[TBL] [Abstract][Full Text] [Related]
5. THAOS - The Transthyretin Amyloidosis Outcomes Survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis.
Coelho T; Maurer MS; Suhr OB
Curr Med Res Opin; 2013 Jan; 29(1):63-76. PubMed ID: 23193944
[TBL] [Abstract][Full Text] [Related]
6. Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments.
Sekijima Y
J Neurol Neurosurg Psychiatry; 2015 Sep; 86(9):1036-43. PubMed ID: 25604431
[TBL] [Abstract][Full Text] [Related]
7. Hereditary transthyretin amyloidosis: baseline characteristics of patients in the NEURO-TTR trial.
Waddington-Cruz M; Ackermann EJ; Polydefkis M; Heitner SB; Dyck PJ; Barroso FA; Wang AK; Berk JL; Dyck PJB; Monia BP; Hughes SG; Tai L; Jesse Kwoh T; Jung SW; Coelho T; Benson MD; Gertz MA
Amyloid; 2018 Sep; 25(3):180-188. PubMed ID: 30169969
[TBL] [Abstract][Full Text] [Related]
8. Clinical and pathological findings in familial amyloid polyneuropathy caused by a transthyretin E61K mutation.
Murakami T; Nishimura H; Nagai T; Hemmi S; Kutoku Y; Ohsawa Y; Sunada Y
J Neurol Sci; 2017 Oct; 381():55-58. PubMed ID: 28991715
[TBL] [Abstract][Full Text] [Related]
9. Three Turkish families with different transthyretin mutations.
Bekircan-Kurt CE; Güneş N; Yılmaz A; Erdem-Özdamar S; Tan E
Neuromuscul Disord; 2015 Sep; 25(9):686-92. PubMed ID: 26115788
[TBL] [Abstract][Full Text] [Related]
10. [Transthyretin Familial Amyloid Polyneuropathy - Disease Profile of a Multisystem Disorder].
Niemietz C; Röcken C; Schilling M; Stypmann J; Uhlig CE; Schmidt HH
Dtsch Med Wochenschr; 2018 Mar; 143(6):427-430. PubMed ID: 29544239
[TBL] [Abstract][Full Text] [Related]
11. Familial transthyretin-type amyloid polyneuropathy in Japan: clinical and genetic heterogeneity.
Ikeda S; Nakazato M; Ando Y; Sobue G
Neurology; 2002 Apr; 58(7):1001-7. PubMed ID: 11940682
[TBL] [Abstract][Full Text] [Related]
12. Cutaneous biomarkers of therapeutic efficacy in early treatment of hereditary ATTR amyloid polyneuropathy with tafamidis.
Cárdenas-Soto K; Dominguez XH; Cortes G; Tsai F; Saniger MDM; Guraieb-Chahin P; Torres-Ocatvo B; Gibbons C; Kelly JW; Freeman R; González-Duarte A
J Peripher Nerv Syst; 2024 Jun; 29(2):221-231. PubMed ID: 38706223
[TBL] [Abstract][Full Text] [Related]
13. Early skin denervation in hereditary and iatrogenic transthyretin amyloid neuropathy.
Masuda T; Ueda M; Suenaga G; Misumi Y; Tasaki M; Izaki A; Yanagisawa Y; Inoue Y; Motokawa H; Matsumoto S; Mizukami M; Arimura A; Deguchi T; Nishio Y; Yamashita T; Inomata Y; Obayashi K; Ando Y
Neurology; 2017 Jun; 88(23):2192-2197. PubMed ID: 28490654
[TBL] [Abstract][Full Text] [Related]
14. Familial amyloidosis with polyneuropathy type 1 caused by transthyretin mutation Val50Met (Val30Met): 4 cases in a non-endemic area.
Andrés N; Poza JJ; Martí Massó JF
Neurologia (Engl Ed); 2018; 33(9):583-589. PubMed ID: 27793437
[TBL] [Abstract][Full Text] [Related]
15. Variable presentations of TTR-related familial amyloid polyneuropathy in seventeen patients.
Cappellari M; Cavallaro T; Ferrarini M; Cabrini I; Taioli F; Ferrari S; Merlini G; Obici L; Briani C; Fabrizi GM
J Peripher Nerv Syst; 2011 Jun; 16(2):119-29. PubMed ID: 21692911
[TBL] [Abstract][Full Text] [Related]
16. "Red-flag" symptom clusters in transthyretin familial amyloid polyneuropathy.
Conceição I; González-Duarte A; Obici L; Schmidt HH; Simoneau D; Ong ML; Amass L
J Peripher Nerv Syst; 2016 Mar; 21(1):5-9. PubMed ID: 26663427
[TBL] [Abstract][Full Text] [Related]
17. Familial amyloid polyneuropathy.
Planté-Bordeneuve V; Said G
Lancet Neurol; 2011 Dec; 10(12):1086-97. PubMed ID: 22094129
[TBL] [Abstract][Full Text] [Related]
18. Drug and Gene Therapy for Treating Variant Transthyretin Amyloidosis (ATTRv) Neuropathy.
Dardiotis E; Kyriakides T
Curr Neuropharmacol; 2023; 21(3):471-481. PubMed ID: 36366846
[TBL] [Abstract][Full Text] [Related]
19. Genotypic and phenotypic presentation of transthyretin-related familial amyloid polyneuropathy (TTR-FAP) in Turkey.
Durmuş-Tekçe H; Matur Z; Mert Atmaca M; Poda M; Çakar A; Hıdır Ulaş Ü; Oflazer-Serdaroğlu P; Deymeer F; Parman YG
Neuromuscul Disord; 2016 Jul; 26(7):441-6. PubMed ID: 27238058
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
